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Knight in Common Armor: An Interview
with Sir John Sulston
Jane Gitschier
I
spent two of my three months on
sabbatical in Cambridge gathering
my courage to invite Sir John
Sulston for an interview. How do you
approach a man who has spearheaded
and labored with his own hands on
three major genetics projects, won a
Nobel Prize, been knighted, and even
had a building named after him?
Perhaps it was the salutation that gave
me pause, before settling ﬁnally on
‘‘dear sir john’’ in an e-mail.
Capped with a head of vigorous
white hair and a face framed with a
matching beard, Sir John has a rock
star recognizability. Thus he captured
my attention one Saturday afternoon
as my 12-year-old daughter and I
bicycled past the Fitzwilliam Museum,
and he pedaled by in the opposite
direction. ‘‘There is the man I’m
hoping to interview!’’ I said as I pointed
out the man in a red shirt.
I told her he was Sir John Sulston. ‘‘Is
he a prince?’’ No, just a knight.
That he had won a Nobel Prize. ‘‘Is he
rich?’’ I don’t think so.
And that he had won it for his work
on worms. ‘‘Does he know that worms
are segmented?’’ Ah, a tricky question!
Not his worms, tiny creatures called C.
elegans. I started to wonder if maybe she
should do the interview.
Sir John was catapulted into the
public light as the spokesperson for the
human genome in the UK. His
experiences in defending the public
genome efforts against the assault of
privatization and patenting, chronicled
in his book The Common Thread: A Story of
Science, Politics, Ethics and the Human
Genome (Black Swan, 2003) were
transformational. Now ofﬁcially retired
from the Wellcome Trust Sanger
Institute (WTSI), he is absorbed in
policy-making for the UK government,
the World Health Organization, and a
variety of nongovernmental
organizations (NGOs). An activist and
humanitarian who still rides his bicycle
to work, who is content to share a small
ofﬁce, and who ponders whether our
species will survive the coming century,
Sir John is an inspirational man, one
who leads by example.
Jane Gitschier: I’d like to start with the
process of looking at worms and
tracing their lineages. When did this
work begin?
John Sulston: It was mid-’70s, I think.
I’m a bit vague because I did all sorts of
different things after joining Sydney’s
[Brenner] group in 1969. One of those
projects led me to being interested in
the cell lineages, because I wanted to
know where the dopamine-containing
cells came from.
I was in the midst of a hobby project,
a method for displaying
catecholamines as bright ﬂuorescent
adducts. After some ﬁddling around, it
worked and gave some beautiful
patterns. It was clear that a very small
subset of neurons contained dopamine
and some contained serotonin. That
was really no big deal.
However, what was potentially a big
deal was that some of those cells
appeared only after the embryo
hatched. There had been a general view
ﬂoating around, one of those urban
myths, that there really wasn’t any
neural development after hatching. So
I thought we should follow this up.
I started looking at these cells with
Nomarski microscopes, of which there
were several around the lab. I was lucky
enough to stumble on a way to just look
at them, without any fancy
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cells came from.
But then, we realized that other
sections of the nervous system also
developed post-hatching. The long and
short of it was that I found myself able
to watch dividing cells.
JG: At some point you moved from
looking not just at neural cell divisions
to looking at the whole thing.
JS: That’s right. Just bit by bit. The very
ﬁrst lineaging was the ventral cord, a
set of motor neurons that make the
organism move in a sinusoidal wave,
backwards and forwards.
Just after that, Bob Horvitz showed
up. He was a hard-core molecular
biologist. He thought all this zoology
stuff was a bit of rubbish. He was fairly
amazed that a guy was sitting there
studying cell lineages.
It was quite an interesting
rapprochement. Bob wrote it up as a
nice thing for Genetics [1980] in which
he described how this happened, how
at ﬁrst he was completely bemused,
how if it didn’t involve a scintillation
counter it wasn’t real science. He
hadn’t realized that this was really
precise, really digital information
coming out. Not sloppy stuff.
So he then became the driving force
to push it to the next stage and do all of
the post-embryonic lineaging. He did
some, I did some.
JG: You talk of this period of a year and
a half when you focused on the
embryonic development, to complete
the entire lineage.
JS: That was later. This is going back to
the history and why people hadn’t
made progress with the fancy Nomarski
microscopes and why I did. Because of
my initial interests, I was looking at the
larvae, which others had completely
ignored.
JG: Because that stage was thought to
be too late?
JS: Yes, because there was this view that
the nervous system wasn’t developing
there anyway. Also, it was difﬁcult
because the worms are wriggling
around. People were interested, but
they killed them or anesthetized them,
and of course, nothing happened
because the worm is unhappy, or dead,
or about to die. And the result was it
was all fairly hopeless.
What I hit on was the idea of putting
living worms down on an agar pad with
some bacteria for them to eat, so they
were happy! And although they were
still moving, they weren’t moving so
fast that you couldn’t follow the cells.
And this is what Bob Horvitz found
me doing, just after I had completed
the ventral cord work, and he joined in.
And then we passed this technique—it
seems a rather grand word for just
looking at worms on an agar patch—on
to people all over the world and it
allowed them to start looking at post-
embryonic development and make use
of mutations and so on.
So there was great excitement about
this. It was the little wonder of that
particular year that suddenly we could
see the cells. And it linked the work
John White was doing on
reconstructions of the neuroanatomy.
He could, from the output of the
lineage work, say which cell was which
and correlate the position of the twig
on the lineage tree and the type of
motor neuron it was producing.
JG: And these reconstructions were by
EM [electron microscopy]?
JS: Yes, and there was a guy named
Nichol Thompson on whom
everything hung because he was able
to cut very long series of sections
without losing any. It was a great deal
of work, but it meant that people
could go through those sections, make
photographs, trace through the stack.
Because there were no gaps, you could
actually follow through the proﬁles of
the axons.
So, then we wanted to know where
these neuroblasts came from—to go
back into the embryo. And this had
been where people had thought to start
because it was easy to have eggs survive
in their hard egg case under the
microscope. But the problem was that
it was hard to follow the cell lineage in
a ball of cells with really no phenotypic
characters.
But there came pressure from the
community to move forward on the
embryo, because of a dispute. Someone
had claimed to have the lineage of the
intestine, and people were doubtful as
to whether he got it right, so I was
asked to arbitrate. So I ended up doing
my ﬁrst bit of embryonic lineaging
using exactly the same method, just
putting the egg under Nomarski optics
and watching and drawing.
I can show you the patterns, if you
want to see the way they’re recorded.
JG: Yes, love to!
[John opens his small Sony PC to a
record dated 5 June 1980. There are a
series of colorful small drawings with
circles and arrows, reminding me of an
American football playbook. We delve
into the drawing (Box 1).]
JG: Now would this page have been in a
bound laboratory notebook?
JS: These are all loose leaf. If you had
come to the house I could have pulled
these things out. All my archives are
there at the moment. They’ll land up at
the Wellcome Trust after a while. So if
the house catches ﬁre we’ll lose them
all. It’s a bit doubtful how many of
these you really want.
JG: Well, how many are there?
JS: Hundreds. This is really only of
historical interest.
The technology for studying the
embryo has improved. John White built
a 4-D microscope, scanning up and
down the whole embryo. And with nice
software, you can ask for images in any
series you want. And this really put
embryonic lineage following on better
footing. This came out about ten years
after my work. Now there is yet another
step, just happening in Bob Waterston’s
lab in Seattle. They are completely
automating lineage mapping by green
ﬂuorescent protein-tagged histones.
JG: Did your mind ever wander while
you were doing this?
JS: You have to be quite focused. I did
really button it down. You don’t need
to draw many pictures when the
nucleus is just changing its
morphology, but you do have to be
really on the ball when the cell goes
through its anaphase and telophase
because that is what you must follow in
order not to be confused.
JG: Were you in a room by yourself?
JS: Oh, yeah.
JG: For all these kinds of experiments?
JS: I always was alone. I ﬁnd it
impossible if there is distraction.
I remember there was a little bit of
conﬂict about this. Some of the others
rather wanted a microscope room, and
that is good because it’s air-
conditioned. In order to keep watching
these you must keep the temperature
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overheat [the worms] when you are
shining bright light down and the slides
get hot. Above 25 8C they start to get
very unhappy.
And in a lot of labs like Bob Horvitz’s
lab at MIT, there is a whole row of
microscopes, and that is true of anyone
now who does this kind of thing. But I
noticed, when I visited there, that they
really don’t talk.
But I remember at LMB [Laboratory
of Molecular Biology, Cambridge],
people would come in and say, ‘‘Oh,
look what’s happening,’’ and they really
wanted to talk about it, and I’d
completely lose it! So I said, ‘‘Look, I
have to have my own room for this.’’
People were feeling, ‘‘Oh, the poor guy
is a bit fussy,’’ but I got my way, and
otherwise I wouldn’t have been able to
do it.
JG: When was it that you got your own
room?
JS: When Bob and I seriously started to
look at post-embryonic lineage. I think
I just made myself sufﬁciently
obnoxious.
JG: So you didn’t listen to music or
anything when you did this?
JS: One thing I did do with the
embryonic lineage, I solved the Rubik’s
cube from scratch. I also made some
Archimedean solids, the regular
polyhedra. I made them out of thin
card and glued them together. So I did
ﬁnd myself little distractions, but
obviously things that didn’t engage me.
JG: Where was Bob?
JS: He was in the room next door. He
was doing various other things as well,
genetics, while I was doing just solid
lineaging. We worked on the ﬁrst
mutants that affected the cell lineage. It
was the beginning, I think quite a nice
catalog.
Bob is a very thorough man. I
remember he made an enormous list of
about 150 psychoactive drugs to try on
the worm. And any time something
happened we would work on it
together. I did more of the following
up, so in addition to the wild-type
notebooks, there are notebooks full of
the mutant images.
JG: What do you think it is about you
that made you particularly good at this
lineage work? Not everyone would have
the patience and the focus to go
through this.
JS: Well, I don’t think I had anything
else much to do at the time.
All of my scientiﬁc projects have
started as hobbies, something to do in
the evenings maybe, and then at some
point you ﬁnd you are taking it
seriously and it becomes your day job.
It was this business of constantly trying
things out and seeing what you can do.
Why me? I don’t know. I enjoyed
looking at the Nomarski objects.
Actually, I think they are awfully
beautiful. I still ﬁnd it amazing that you
have this optical trick that allows you to
visualize what is only a transparent
image, after all. Because of the cross-
polarized beams, you image the
refractive index. The detail you see! I
could watch it forever.
And then there was the group thing. I
emphasize Bob, but the whole group
was involved. And there was this feeling
that the lineage was something that
people really wanted.
That’s the other thing—I actually
quite like to please.
JG: You never entered the professorial
track, but remained a staff scientist at
the LMB. Did that suit your
temperament?
JS: Absolutely. It was a very good ﬁt for
me. If there was something that I
thought was important and worth
doing, I could just focus on that, and
the only pressure was from family life.
It meant you had time to sort all this
out and not feel the pressure that you
had to cut corners or guess.
The negative is that we don’t do
much teaching. I feel in a way we’re not
such good citizens because teaching is
important. Also, we didn’t have
independence. As long as I was at the
LMB working on worms, Sydney was
my boss.
JG: Sitting there in a chair, focusing on
this process—it has the feeling to me of
a meditative practice. Did you have a
kind of spiritual experience?
JS: I would only use the word spiritual
in the loosest sense. I use the word
beauty straightaway, and I think that
touches on it. Enjoying this sort of
thing is certainly part of humanity. And
I’m the secular humanist kind of
person, who thinks that we have a love
of beauty built into us.
I feel the same way, hiking in
Scotland in Ben More. [He points out
his laptop screensaver with his photo of
the vista, stippled with icons].
JG: And how marvelous to watch
something that nobody has ever seen
before.
JS: Oh yes! The most exciting thing to
do is to go somewhere where nobody
has been before. It was hugely exciting,
looking at those cells dividing for the
ﬁrst time and knowing that I could see,
I could ﬁnd out. It’s true all the way
through science.
Actually you hold it to yourself
[speaking in a hushed voice, as he folds
his arms across his chest] when you’ve
got something nice, but then within a
few minutes you’ve got to rush out.
JG: What were the times you rushed
out?
JS: Seeing those ﬁrst cells divide!
Because the previous work looking at
ﬁxed cells just hadn’t gone anywhere.
No one had managed to see anything.
But I was just sitting there and suddenly
I knew it was all open. Because I could
see that ﬁrst cell divide and I knew I
could see its daughter divide.
JG: Did you wait for its daughter to
divide before rushing out of the room?
JS: Of course! The very ﬁrst viewing I
carried on right to the end. I was
entranced. And those divisions are
quite quick. Within an hour, it’s already
beginning to swell up to the next stage.
JG: But another moment might have
been when you saw the ﬁrst cells dying
off.
JS: That was a rather slower dawning of
what was going on. At ﬁrst, I didn’t
know what to make of it at all. There
must have been some discussion with
others about what on earth was
happening. I don’t know if I or
someone else ﬁrst realized that this
might have been a cell death. I just
knew that something strange was going
on, and this thing had disappeared, so
obviously it was a cell death. But I
probably wasn’t sufﬁciently well-read
to know the background to this and to
know about cell death being a
programmatic feature in development.
JG: Let’s tear ourselves away and move
forward to the nematode genome work.
JS: At the end of the embryonic lineage
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that up and it was done. And everybody
said, ‘‘Well, now of course you do
mutants.’’
But it was a bit competitive by then.
There were all sorts of people out there
doing it, including my ex-student. I
wasn’t sure I really wanted to go and
compete. It’s a bit of a mingy thing to
say, but there you go.
I like to do things on my own, you
see. I don’t like being in the middle of
buffaloes on the plain kicking up the
dust. So I was looking around for
something else to do more on my own.
A rather dramatic ﬂash came when I
heard a seminar by Matt Scott
describing the Antennapedia walk,
working out the map of the region of
Drosophila, and I said, ‘‘We’ve got to do
this [in worms], but not just one bit—
the whole thing!’’ Because at that point
there was this absolute bottleneck with
the worm people.
I remember discussing this with Bob
Horvitz and Jonathan Hodgkin. And I
remember being quite worried. It
wasn’t at all clear to me that the worm
was going to make it! We lacked some
of the perquisites of the ﬂy, the
polytene chromosomes in particular.
The ﬂy came with this built-in physical
map, which the worm didn’t. And one
of the consequences was that our
students were spending years, their
whole Ph.D. theses, isolating a gene. It
was awful. John White complained
about this. He said the seminars were
deadly, mind-numbing to sit and listen
to each student explain how they had
failed to clone their gene.
So after hearing Matt speak, I came
back and talked to people about how
we’re going to do this. And I said
‘‘Look, we’re going to start.’’ So I was
given some space in the new bit at the
LMB to do this.
JG: Did you ever imagine that it would
turn into what it eventually became?
JS: No, absolutely not. I just saw it as a
speciﬁc problem and it was very much
oriented on the map.
JG: And the recovery of clones.
JS: Yes. Just sort the thing out and have
the clones lined up in the freezer, so
people could take them and have a
reasonable correlation between the
physical and genetic map. That was it—
that was to be the project for the ’80s.
That really was a big change in my
life, and that led directly beyond, not
only to the worm sequence, but then to
the human. As night follows day, to this
place being built. And everything that
happened in the ’90s around here.
JG: Was Alan Coulson just leaving
Sanger’s lab at that time?
JS: That was the other very good thing
that happened to me, and probably
without that, it would not have worked.
Alan chose to join me when Fred
Sanger retired. I had already been
working, rather ineffectively, on it.
Alan is superb at making things work
and parallelizing. So we had a hell of a
ﬁne collaboration and things started to
move immediately when he came.
JG: And it sounds as though you were
engaged with this new project as much
as you were with the old one.
JS: Exactly. It was an important
problem. And we needed it [the map].
What I did for much of the ’80s was
make the libraries, for some reason,
because Alan was getting on with the
biochemistry. But the thing I mainly
did was to learn computer
programming. I took that up and wrote
all the software. I had no intention of
doing that, but there was no one else to
do it, and we needed it urgently. So one
weekend, I said, ‘‘I’m just going to start
writing Fortran.’’ Roger Staden started
me off and it snowballed into this huge
program, very unprofessionally written,
but it worked.
When we had done two or three
years of this and more or less exhausted
the approach we had, which was
looking at cosmids, we became aware
there were gaps. Bob Waterston came
and we all worked on this. From the
mid-’80s this was a formal and equal
collaboration. And it was resolved by
Bob’s going back and using the YAC
[yeast artiﬁcial chromosome]
technology that had just been
developed in Maynard’s [Olson] lab.
And suddenly we had the whole map.
JG: OK, let’s fastforward to more recent
history at the Sanger Institute. Why did
you decide to step down as the director
in 2000?
JS: Well, the decision was made in 1998,
and the people I’d worked with weren’t
terribly happy about it—a bit rocking
the boat.
We were just a bunch of amateurs,
the seven of us on the board of
management, and the staff did get very
unhappy after about three years when
the numbers went up to about 100, and
the Institute wasn’t being running
along stable, robust, and predictable
lines. So we had some management
training that was quite interesting and
extremely effective.
We all underwent a bit of
psychoanalysis of our various
characteristics. When it came to the
results from me, the facilitator said
‘‘Well, you’re the sort of person who
gets there in the end by a very muddled
route and you end up emerging
backwards through the hedge covered
in bits of glass.’’ I was rather ﬂattered; I
thought he got that about right!
And that’s back to your question
about doing things differently. If you
worry too much about how you’re
going to do something, you don’t do
anything.
JG: So, back to leaving the
directorship . . .
JS: It was like leaving the lineage work. I
felt I had done what I could, and I felt
quite strongly that it was going to
plateau, and I wasn’t a proper director,
in the sense of really enjoying running
things. I didn’t have yet another big
project that would move things on. It
would become more of an
administrative thing. What Allan
[Bradley, current WTSI director] has
done is to hire a lot of new faculty
doing a lot of different things and the
place has become much more like a
university department with a lot of the
high-throughput stuff still here.
I really can’t run a department in this
way. It was a single project thing for
me.
JG: Ah, you are focused.
JS: But I had enough of a sense of
preservation of the Institute that I was
always enthusiastic about having
multiple things going on.
JG: When you stepped down, did you
want to relinquish the administrative
responsibility but continue with the
genome project?
JS: I didn’t have a particular thing in
mind. But at that point, there was still
too much to do. In 1998 we had
published the worm in incomplete
form and still had a lot to do on
closure. The human genome was just
reaching its crescendo. And I told
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that. I worked as hard as ever on the
worm and on the human right through
2001, and then things began to fade a
bit. And by that time I’d got the notion
of writing a book with Georgina [Ferry].
So somehow, I never really
considered what I would do next
because the time was full.
JG: I’ve also heard that when you win a
Nobel Prize your time is no longer your
own.
JS: It’s very demanding. You have to
sort it out. It’s impossible.
JG: Do you still have a lab here?
JS: No. A couple of years ago I became
Emeritus with the Wellcome Trust. I
pop in at least once a week, often on
Sunday morning when it’s quiet.
Sometimes with a speciﬁc intent or a
meeting, or I’ll meet people in passing.
I use the library quite often. I still like
using books.
JG: Looking back, was there one period
that sticks out as being the most joyful
or the most productive or the most
intellectually exciting?
JS: I wouldn’t discriminate. Something
I want to emphasize is how distinct they
are, really. My postdoctoral work on
prebiotic chemistry with Leslie Orgel
was hugely exciting, and before that I
enjoyed being a student with Colin
Reese just making some of the early
oligonucleotides. But there is this sense
that I, probably more than most, have
jumped from one thing to another.
JG: Yes, but with a rather slow
periodicity. You couldn’t be faulted for
leaving a project before it was
completed!
JS: Yes, a classic seven years. Well, I
suppose the genome is rolled itself
together into two lots of seven years.
JG: When I read The Common Thread, I
was struck by the image of you and the
public human genome project as a ship
under a state of attack. That you were
thrust into a position of having to
suddenly defend yourself and your
approach against the assault of
entrepreneurial javelins, and to work
even harder. What a huge waste of time
and resources the battle caused!
JS: It was hugely complex. And that was
exactly why things changed again. And
any immediate thought of restarting a
group went out of the window! It was a
waterfall of things happening! And
then, all I wanted to do was to write an
account of it afterwards and talk about
it because I thought it was important.
But a lot of people say, ‘‘Well, this is
the way the world is. You should know
that!’’ And that I ﬁnd very depressing.
There is a sense in which we are
struggling to come to terms with a very
rapacious free market, in all sorts of
areas. And this little particular area is
what I was trying to express in the
book.
There is a lot of rewriting of history
now, but it was just like that—the
assault with javelins.
What I’ve never been willing to agree
to is that somehow or other it helped!
The standard story, because everybody
wants peace, is to say, ‘‘Well, yes this
competition did accelerate things.’’
I think that is absolutely wrong. All it
did was to speed up getting this fake
release of the draft sequence, which was
90% complete. It was a political deal. It
was an election year [2000]. The White
House had really become unhappy
about what was going on. It was a silly
deal, but it meant peace.
JG: Have you met Craig Venter?
JS: The last time I saw him was at the
Gairdner. One of the things we’ve had
to do since this is to all go and get
awards together. What else can you do?
You can’t be in a state of perpetual
warfare. And what you said about it
being a huge waste of time is absolutely
right.
JG: Do you think Americans are most
aggressive about privatization? Do you
think such a thing could have
happened in England?
JS: Well, we have rapacious
entrepreneurs here, too, but America is
bigger and has the world’s richest
corporations.
Of course, there was a battle within
the US, which was almost divided down
the middle—the neoconservative and
Democrat wings. Yes, because the
resources are there, I think these
battles are more likely to be fought out
in America.
But of course, increasingly so, they
are also fought on the global campus,
and that’s the other reason why I think
this is so important. We are wasting
time, I think, to get globalization right,
and people ought to be paying more
attention to stories like this because it
shows ways that things can be run
stably in the future and ways in which
they can’t.
If you have unbridled competition as
the basis for international relations,
then we are going to die. Because we
don’t have the basis for sorting out the
environment or people’s lives or
anything in a more ethically
advantageous way. If everything is done
through the World Trade
Organization, and everything is done
for who can get the most revenue, we’re
sunk.
JG: Were you thinking, when you made
plans to retire, that you were just going
to end it [your career]?
JS: No, I knew I wasn’t just going to end
it, because I had too much to do. What I
hadn’t planned on was what it might
lead to. I’ve dealt with how things have
evolved and haven’t started new ones.
That was not a plan.
JG: Can you articulate your role now?
JS: I am occupied with various small
attempts to lubricate the interface
between the science of genetics, human
genetics, and the public—all of us.
I’m the vice-chairman of the Human
Genetics Commission, a part of the
Department of Health in the UK. The
aim is to have a body of experts, about
twenty of us in various areas—industry,
science, nursing, consumer affairs—all
people with a stake in genetics in
general. The thing I’m most concerned
with is genetic equity. Simply
nondiscrimination, because it’s a real
issue.
Another thing I’m doing informally
is speaking in support of various NGO
activities in Geneva. I’m interested in
fair trade. Medecins sans Frontieres
and Oxfam both run campaigns on this
which I’ve supported. There is the
Drugs for Neglected Diseases Initiative,
which I support.
There is also an active campaign
going on in WIPO [World Intellectual
Property Organization] to bring a
development agenda. The background
to all this is immensely complex. In the
WTO [World Trade Organization], the
TRIPS agreement [Trade Related
Aspects of Intellectual Property Rights]
is coming to a head and is forcing all
but the very poorest countries to sign
up for a high level of enforcement of
law as practiced by the G8 countries.
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longer be able to produce generic
drugs freely. It will greatly increase the
powers of the major corporations.
One must not be cavalier and say,
‘‘This is all bad and we must sweep it
away,’’ but unquestionably the current
system we have for funding medical R
and D leads to production of
pharmaceuticals only for the rich
markets.
JG: What about the Gates Foundation?
JS: The Gates Foundation is the only
major source of revenue for these
initiatives right now. And all the public/
private partnerships are dependent on
Gates money at the moment.
It’s still not enough and it’s not
sustainable enough, even though
Warren Buffett has just contributed his
money as well. So perhaps the world
will be run by rich men’s charities. I
ﬁnd that rather uncomfortable. Of
course, the reason we are here in this
building and sequencing the human
genome is because of pharmaceutical
stock from the Burroughs Wellcome
Foundation.
So things are a mess. What we’re up
against is whether we can have real
intergovernmental support for drug
development that will not depend on
the marketplace. PLoS Biology
[www.plosbiology.org] published a new
concept for an international treaty on
biomedical research. Jamie Love, who
runs his own NGO called CPTech in
Washington, and Tim Hubbard, who is
here, have put together a scheme for an
international accord by which
countries contribute to a global
healthcare R and D fund. This can be
done through the free market if people
wish, but equally could be done in an
open access sort of way, through
institutions. It would be much more
transparent. Above all it would allow us
to devote funding not just to the
revenue-earning things in the rich
markets. But we could start to address
the neglected diseases.
It would generate an enormous
worldwide fund, far bigger than the
Gates Foundation. This is the kind of
proposal that really raises the ire of the
pharmaceutical representatives.
It would be a hugely cohesive thing in
the world if we were able to move
towards a global health system.
But I fear that the force is going the
other way. The things I’ve heard the
representatives of the pharmaceutical
manufacturers say in Geneva—
the blatant, vicious manipulation of
ﬁgures to prove their case! And
it sounds silly—but just the
rudeness!
JG: The arrogance?
JS: Yes, exactly. They say: ‘‘You’re
wasting your time. Nothing will ever
change.’’ How appalling!
JG: Maybe these kinds of problems
make the human genome project seem
not so complex!
JS: When I give speeches to people, I do
tend to end up as a prophet of doom,
saying we really maybe won’t live
another century. And one of the ways
we may not do it is to continue along
this path.
JG: On a much lighter note, I have a
ﬁnal question. I will never meet a
knight again, so . . .
JS: There are quite a lot of them about,
actually.
JG: There are?
JS: This is quite interesting. For a long
time the guys in LMB didn’t accept
knighthoods. Max Perutz, for example.
And not long before he died, I asked
him about this. He said he didn’t
because it would set him apart from the
staff.
Now, it’s important to look at
background on this. Those guys, when
they set up the LMB in their new
building, set up a single canteen. More
or less contemporaneously, I was in
research in the Chemistry Lab, and
there were three canteens—one for the
faculty, one for the students, and one
for the technicians. Absolute class
distinction, and that is the way it was
always done.
So, in that context, Max didn’t want
anybody to be put in a position of
uncertainty about how to address him.
He was just ‘‘Max.’’
Max was not a sort of hale fellow. He
was very quiet and quite formal, so
people might have been inclined to
give him his title. He was a very
properly spoken kind of guy. And it was
wonderful to learn that underneath was
this well of egalitarianism.
JG: Fascinating.
JS: It is a real problem with
knighthoods.
JG: Sorry, I must laugh, sounds like a
problem with putting on your armor or
something!
JS: The reason I said that there are
quite a lot of them is because there are!
It is not the top honor. You also have
MBE, OBE, CBE, then knight, then
various higher ranks.
JG: You just jumped in at knighthood?
JS:? Yes. People put you up for these
things. You just get a letter one day
saying you are being offered a
knighthood, are you going to accept it?
There is just this curious convention
that with the knighthood you can put
‘‘Sir’’ in front of your ﬁrst name, not
your second name.
The whole thing is absolutely
ridiculous, really. But I was persuaded
that it was quite a good thing for
science to be recognized in this way in
this country. Aaron Klug was the ﬁrst
one to accept it at the LMB. And he
began to talk to us about how accepting
knighthood was good for science.
Otherwise science was the poor
relation and business and arts were
recognized. Of course, some people ask
how could I accept this—republicans
and the [Manchester] Guardian—and I
say this has nothing to do with the
Queen. Although you do meet the
Queen.
JG: You do?
JS: Yes, the sword on the shoulder. It’s
all pretty odd. So we either cold-
shoulder it, or we say scientists are just
as good as anybody else.
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of Sir John Sulston
JS: Let me explain what you see on this page.
This is a particular bunch of cells at a particular
time. Here are the minutes during which I am
watching it. Drawn every five minutes or so,
over a span of about three hours. I broke it
into stages—I followed a particular cell and its
descendants.
And then I put these different bits together. It
was based on the assumption that the lineage
would be fixed. And, of course, as I did it, I
checked to make sure that things really did
always happen the same way, and indeed they
did, apart from very rare cases where cells
determine their fate by their interaction.
JG: So you’ve got red pens, green, blue, black
pens, drawing quickly every five minutes. This
is the kind of mundane thing I’m interested in.
JS: I thought it might amuse you. You’ve got
red, green, black, blue, and purple on this one.
JG: This looks like Russian to me [as I pointed
to a cell labeled ‘‘MStpaaapa’’].
JS: These are the names of cells. MSt is one of
the primary blast cells, and that means the
posterior daughter, and the anterior daughter,
and the anterior daughter and the anterior
daughter and the posterior daughter and the
anterior daughter. And there is a question
mark! Wasn’t sure if I got that right or not.
I should explain the colors. They are depth.
Red is out the top, then down a bit is green,
down a bit more black. This is the problem
with movies, you get all these images at
different depths and then you’ve got to try
putting them together. Now, the drawing
you’re putting together over a limited area at
the time. So I’m quite certain of what I’m
looking at. However, I do have to follow about
ten cells at a time.
JG: What are the hatch marks here?
JS: That is a cell death, one of the things that the
worm has become rather well-known for.
Programmed cell death was known about in
mammals, but there were no handles on it. But
because the worm has a fixed cell lineage and we
knew which cells were going to die, we could
look for mutants that change that pattern. The
hatching means that the cell has gone very
refractive—very bright—in Nomarski image.
JG: Are these the same color codes you used
with the larvae?
JS: Yes.
JG: So you are actually thinking in color here.
JS: It’s an approximately spectral range—red at
one end, violet at another—so it is easier to
remember. A cell higher in the focal plane is red.
These pictures have actually been quite
interesting. In fact there is a whole bunch of
these notebook pages in Kettle’s Yard in
Cambridge [‘‘Lines of Enquiry: Thinking through
drawing,’’ a fascinating exhibition by Barry
Phipps http://www.kettlesyard.co.uk/exhibitions/
archive/linesofenq.html].
JG: How did you settle on this kind of
representation?
JS: Desperation.
The larva is more or less flat, and when a cell goes
past another, you can keep on drawing. But what
happens when a cell goes over another cell, oh
dear, I get lost. So, I grabbed the nearest color
pen and said, ‘‘Right, if it goes up it’s red.’’ When I
came to the embryo I was really equipped to
code it. So this is a ball within a ball—ten cells
sitting with several hundred cells at this stage.
JG: Love the squiggle—what is that all about?
JS: I made a mistake. And I started again.
JG: I see you are picking up from where you
left off on the fourth of June. You had to find a
new embryo and maybe wait around for it to
be of the right age.
JS: I realized that I could come straight in if I
picked the right stage embryo. And there is
quite a business of doing this, sorting embryos
and looking around for the one you want and
finding the right orientation. You can pick up
landmarks that are unique.
JG: So you started your day picking the one or
two embryos that you were going to look at.
JS: That’s right. Now on this one, I want to
know what this particular cell is, and that is all
I want to know. There is something called M1
coming out, sister to a cell death. There was
something about that I didn’t know, but here I
can make a conclusion.
doi:10.1371/journal.pgen.0020225.g002
PLoS Genetics | www.plosgenetics.org December 2006 | Volume 2 | Issue 12 | e225 1955